Aram Andrew Mangasarian

Aram Andrew Mangasarian

Amministratore Delegato presso TME PHARMA N.V.

54 anni

Health Technology

Consumer Services

Relazioni attive

Nome	Sesso	Età	Società collegate	Collaborazione
Bertram Köhler	M	53	TME PHARMA N.V. NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.	6 anni
Joseph deBethizy	M	74	TME PHARMA N.V. NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.	8 anni
Walter Wenninger	M	86	TME PHARMA N.V. NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.	-
Sven Klussmann	M	-	NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.	27 anni
Cornelis Alexander Izeboud	M	53	TME PHARMA N.V.	4 anni
Olivier Litzka	M	56	TME PHARMA N.V. NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.	-
Maurizio PetitBon	M	76	TME PHARMA N.V.	8 anni
Jarl Ulf Birger Jungnelius	M	73	TME PHARMA N.V. NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.	7 anni
Susan Coles	F	58	TME PHARMA N.V.	3 anni
Karen Ophoff	F	-	TME PHARMA N.V.	23 anni
Denis Lucquin	M	67	NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.	-
Peter Johann	M	67	NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.	-
Ewelina Staniuk	F	-	TME PHARMA N.V.	6 anni
Heike Balzer	M	-	TME PHARMA N.V.	24 anni

Mostra altro

Grafico relazionale

Relazione in diverse aziende

Relazioni precedenti

Nome	Sesso	Età	Società collegate	Collaborazione
Iain Peter Murray Buchanan	M	72	NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.	8 anni
Alain Herrera	M	74	ISOFOL MEDICAL AB	5 anni
Robert Marchesani	M	63	ISOFOL MEDICAL AB	4 anni
Jan Birger Fredrik Toernell	M	64	ISOFOL MEDICAL AB	-
Martine van Vugt	M	71	TME PHARMA N.V.	2 anni
Rolf Magnus Björsne	M	60	ISOFOL MEDICAL AB	5 anni
Matthias Baumann	M	-	NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. TME PHARMA N.V.	6 anni
Paula Boultbee	F	65	ISOFOL MEDICAL AB	5 anni
Lennart Christer Jeansson	M	83	ISOFOL MEDICAL AB	2 anni
Anna Belfrage	F	62	ISOFOL MEDICAL AB	4 anni
Gregory Weaver	M	68	TME PHARMA N.V.	1 anni
Jens-Peter Fürste	M	-	TME PHARMA N.V.	-
Frank Morich	M	69	NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.	2 anni
Hubert Birner	M	57	TME PHARMA N.V.	-
Thomas Klein	M	-	TME PHARMA N.V.	-
Donald Munoz	M	56	NOXXON Pharma AG NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.	2 anni
Bryan Jennings	M	-	TME PHARMA N.V.	1 anni
Jenny Sundqvist	F	53	ISOFOL MEDICAL AB	-
Tony Gustavsson	M	-	ISOFOL MEDICAL AB	-

Statistiche

Paese	Relazioni	% del totale
Germania	24	72.73%
Svezia	9	27.27%

Età delle relazioni

Attive

Scorse

Uomo

Donna

Amministratori

Dirigenti

Provenienza delle relazioni

I nostri contenuti gratuiti ti aiutano a mettere al sicuro e ad aumentare la performance dei tuoi investimenti

Assicurare i miei Investimenti

fermer